C2i Genomics, which claims its software can accurately detect residual cancers by analysing genome sequences, raises $100M Series B led by Casdin Capital
Context & Ripple Effects
Casdin Capital is quickly becoming the defining backer of AI cancer diagnostics: three months after leading Paige's $100M Series C, it leads C2i Genomics' identical-size Series B — two nine-figure checks into the same thesis in a single quarter.
The round also sharpens a modality split inside the category. While Paige, Imagene AI, and Ibex Medical Analytics detect cancer from digitized biopsy images, C2i claims accuracy from genome sequences alone — meaning the biggest money is now backing both sides of how cancer will be computationally detected.
First-order effects
- C2i Genomics enters its residual-cancer-detection race with $100M at Series B — roughly the total Paige had accumulated through multiple rounds before its own Series C — giving it unusually deep runway to validate a sequencing-based approach against established biopsy-imaging rivals.
Second-order effects
- Image-based competitors face a funding benchmark: Ibex Medical Analytics answered its $38M Series B with a $55M Series C by 2023, and Imagene AI raised a $18.5M Series A — each raise now measured against Casdin-backed peers raising twice as much per round.
Third-order effects
- With DNAnexus having raised a $100M Series G for cloud genomics analytics months earlier, the infrastructure layer under sequencing-based diagnostics is being capitalized in parallel — pointing toward consolidation where whichever modality proves clinically superior absorbs the other's market.
The trend: Specialist life-science investors are concentrating nine-figure bets on AI cancer detection across both imaging and sequencing modalities, effectively picking winners by cheque size.